eli lilly tirzepatide trial Obesity Drug Reduces Body Weight by 20 Percent in FDA approves Eli Lilly's tirzepatide

How It Works By acting on the GIP and GLP-1 receptor pathways, tirzepatide may help some patients reduce hunger and cravings, which can make a reduced calorie eating pattern easier to maintain

This may improve patient care experience, adherence, and contribute to improved long-term outcomes

However, further clinical and basic research are needed to explore its underlying mechanisms

GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally to signal fullness, slow digestion, and help regulate blood sugar

This personalized approach leads to more effective results and a better overall experience

Available from: Fallows E, Ells L, Anad V